Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Irbesartan/hydrochlorothiazide

Drug Profile

Irbesartan/hydrochlorothiazide

Alternative Names: Avalide; Avapro HCT; CoAprovel; Karvezide

Latest Information Update: 31 Mar 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi-aventis
  • Class Antihypertensives; Benzothiadiazines; Biphenyl compounds; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Diabetic nephropathies; Hypertension

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 31 Mar 2015 Launched for Hypertension in Algeria, Morocco and Philippines (PO) before March 2015
  • 03 Oct 2012 Bristol-Myers Squibb intends to terminate its licence for irbesartan/hydrochlorothiazide in all countries, effective 1 January 2013
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top